Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Optaflu vs Agrippal in Adults and Elderly
NCT00560066Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Primary completion
- Jul 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of TIVc in seasonal influenza (2 arms), sponsored by Novartis. Primary endpoint: Number of Subjects Who Reported At Least One Reactogenicity Sign at 1 week. Started Nov 2007; status: completed.
02
Drugs
TIVc
03
Conditions
seasonal influenza
Beyond the preview
Go deeper on NCT00560066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560066.